BriaCell Therapeutics announced the closing of its best-efforts public offering, raising approximately US$30 million through the sale of 5,366,726 units. Each unit comprised one common share or a pre-funded warrant in lieu of a share, together with one warrant. The offering was oversubscribed relative to initial indications of interest, reflecting strong investor demand for the Company’s immunotherapy pipeline.

The warrants included in the offering began trading on the Nasdaq Capital Market under the symbol “BCTXL” on January 14, 2026. Each warrant is exercisable immediately and will remain valid for five years from issuance. By separating the warrants from the underlying equity, BriaCell provides investors optionality to increase their exposure to the Company’s clinical-stage assets without immediate dilution to the existing share base.

BriaCell plans to allocate net proceeds toward working capital requirements and general corporate purposes, with a primary focus on advancing its lead candidate through ongoing Phase II studies in metastatic breast cancer. A portion of the funds will support expanded manufacturing capacity for the Company’s proprietary cell-based platform and enable strategic partnerships aimed at broadening the immunotherapy pipeline into additional solid tumor indications.

ThinkEquity acted as sole placement agent for the offering, leveraging its expertise in life sciences financings to execute the transaction efficiently. The offering was registered on Form S-1 (File No. 333-292388), which became effective on January 13, 2026, and a related registration under Rule 462(b) was filed the same day. All necessary prospectus supplements have been filed with the SEC, ensuring compliance with U.S. securities laws.